Oestrogen therapy and the menopausal syndrome

Area of Science:

• Menopause research
• Pharmacological interventions
• Women's health

Background:

• Menopausal symptoms significantly impact women's quality of life.
• Hormone replacement therapy is a common treatment for menopausal symptoms.
• Objective assessment of treatment efficacy is crucial.

Purpose of the Study:

• To evaluate the efficacy of conjugated equine estrogens (Premarin) in treating severe and less severe menopausal symptoms.
• To differentiate between direct estrogen effects and placebo effects on psychological and physical symptoms.
• To assess the reliability of patient-reported outcomes versus standardized scales.

Main Methods:

• Two double-blind, placebo-controlled trials were conducted.
• Trial 1: 64 patients with severe symptoms over 4 months.
• Trial 2: 61 patients with less severe symptoms over 12 months.
• Graphic rating scales were used for symptom assessment.
• Standard psychiatric scoring systems (Beck, GHQ, Eysenck) were also employed.

Main Results:

• Premarin showed statistically significant improvements in 12 psychological and symptomatic scores in the severe group.
• Improvements in memory and anxiety suggest a direct estrogenic effect independent of hot flush relief.
• In the less severe group, Premarin improved 5 scores.
• Patient self-assessment of skin appearance was unreliable due to a strong placebo effect.
• Standard psychiatric tests were insensitive to changes, while graphic rating scales were effective.
• Minor side effects like leg cramps occurred, but no deep vein thrombosis was detected.
• No significant changes in blood pressure were observed; a slight decrease was noted.

Conclusions:

• Conjugated equine estrogens (Premarin) effectively alleviate various menopausal symptoms.
• Estrogen may exert direct positive effects on mental state, separate from symptom relief.
• Graphic rating scales are superior to standard psychiatric tests for assessing menopausal symptom changes.
• Patient self-reporting on skin appearance is unreliable in menopausal studies.
• Premarin is safe concerning blood pressure and thrombosis risk.